[EN] ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS [FR] CYANOÉTHYLPYRAZOLO PYRIDONES ACYCLIQUES EN TANT QU'INHIBITEURS DE JANUS KINASE
Enantioselective Ketone Hydroacylation Using Noyori’s Transfer Hydrogenation Catalyst
作者:Stephen K. Murphy、Vy M. Dong
DOI:10.1021/ja4021974
日期:2013.4.17
An enantioselectiveketone hydroacylation enables the direct preparation of lactones from keto alcohols. The alcohol is oxidized in situ to an aldehyde, obviating the need to prepare sensitive keto aldehyde substrates. Noyori's asymmetric transferhydrogenationcatalyst was applied to address challenges of reactivity, chemoselectivity, and enantioselectivity.
ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
申请人:DINSMORE Christopher
公开号:US20160272634A1
公开(公告)日:2016-09-22
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
申请人:Merck Sharp & Dohme Corp.
公开号:US10059705B2
公开(公告)日:2018-08-28
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
本发明提供的式 I 化合物是 JAK 抑制剂,因此可用于治疗 JAK 介导的疾病,如类风湿性关节炎、哮喘、慢性阻塞性肺病和癌症。
[EN] ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYANOÉTHYLPYRAZOLO PYRIDONES ACYCLIQUES EN TANT QU'INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146493A1
公开(公告)日:2014-09-25
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.